Background: Lung cancer is the leading cause of cancer-related death in Australia, accounting for 18.7% in 2017; and an estimated incidence of 43 cases per 100,000 persons in 2013, making it the 5th most common cancer. Many genetic abnormalities are essential in driving tumorigenesis. Anaplastic lymphoma kinase (ALK) gene rearrangement is responsible for 3–7% of all non-small cell lung cancers (NSCLC); which are responsive to tyrosine kinase inhibitors. Therefore, detection of such genetic abnormalities has become mainstay practice in the diagnostic workup for lung cancers. READ ARTICLE
Pathology DOI:10.1016/j.pathol.2018.09.044
Authors: M. Huang, A. Chou, D. Riley, Y. Kim, R. Lukeis, M. Qiu